Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC vs VKA After Cardiac Surgery
NCT04002011Phase 2Withdrawn
- Sponsor
- Université Laval
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dabigatran etexilate oral solution, rivaroxaban, apixaban, edoxaban in Atrial fibrillation (AFib), atrial flutter (AFL), venous thromboembolism (VTE), valvular heart disease (VHD), sponsored by Université Laval. Planned start Mar 2022; status: withdrawn.
02
Drugs
dabigatran etexilate oral solutionrivaroxabanapixabanedoxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)venous thromboembolism (VTE)valvular heart disease (VHD)
Beyond the preview
Go deeper on NCT04002011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002011.